Dietmar Schwab

1.5k total citations
26 papers, 1.1k citations indexed

About

Dietmar Schwab is a scholar working on Molecular Biology, Ophthalmology and Oncology. According to data from OpenAlex, Dietmar Schwab has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Ophthalmology and 8 papers in Oncology. Recurrent topics in Dietmar Schwab's work include Retinal Diseases and Treatments (9 papers), Drug Transport and Resistance Mechanisms (6 papers) and Retinal Imaging and Analysis (4 papers). Dietmar Schwab is often cited by papers focused on Retinal Diseases and Treatments (9 papers), Drug Transport and Resistance Mechanisms (6 papers) and Retinal Imaging and Analysis (4 papers). Dietmar Schwab collaborates with scholars based in Switzerland, United States and United Kingdom. Dietmar Schwab's co-authors include Jörg Huwyler, Sonia Poli, Ali Tabatabaei, Holger Fischer, Piotr Szczęsny, Jayashree Sahni, Everson Nogoceke, Shamil Sadikhov, Sunil Patel and Pravin U. Dugel and has published in prestigious journals such as Hepatology, JNCI Journal of the National Cancer Institute and Hypertension.

In The Last Decade

Dietmar Schwab

25 papers receiving 1.1k citations

Peers

Countries citing papers authored by Dietmar Schwab

Since Specialization

Citations

This map shows the geographic impact of Dietmar Schwab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dietmar Schwab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dietmar Schwab more than expected).

Fields of papers citing papers by Dietmar Schwab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dietmar Schwab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dietmar Schwab. The network helps show where Dietmar Schwab may publish in the future.

Co-authorship network of co-authors of Dietmar Schwab

This figure shows the co-authorship network connecting the top 25 collaborators of Dietmar Schwab. A scholar is included among the top collaborators of Dietmar Schwab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dietmar Schwab. Dietmar Schwab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GRADUATE I AND II: Revisiting the key findings from two Phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimer’s disease (AD) 2023 ·Alzheimer s & Dementia ·Christopher Lane, Janice Smith, Richard Perry, Timo Grimmer, Claire J. Lansdall, Nicola Voyle, Paul Delmar, Tobias Bittner, Gregory Klein, Dietmar Schwab, (unknown), Stephen Salloway, Jeffrey L. Cummings, Monika Baudler, Paulo Fontoura, Rachelle S. Doody, (unknown)	0
2	A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration 2021 ·Translational Vision Science & Technology ·(unknown), Dietmar Schwab, Valérie Cosson, (unknown), Norman A. Mazer, Nicolas Frey	6
3	Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration 2020 ·JAMA Ophthalmology ·Jayashree Sahni, Pravin U. Dugel, Sunil Patel, Mark Chittum, Brian B. Berger, Marta del Valle Rubido, Shamil Sadikhov, Piotr Szczęsny, Dietmar Schwab, Everson Nogoceke, Robert J. Weikert, Sascha Fauser	92
4	Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema 2019 ·Ophthalmology ·Jayashree Sahni, Sunil Patel, Pravin U. Dugel, Arshad M. Khanani, Chirag Jhaveri, Charles C. Wykoff, Vrinda Hershberger, Meike Pauly-Evers, Shamil Sadikhov, Piotr Szczęsny, Dietmar Schwab, Everson Nogoceke, Aaron Osborne, Robert J. Weikert, Sascha Fauser	179
5	Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus 2018 ·Drug Research ·Sachiya Ikeda, (unknown), Dietmar Schwab, Agnès Portron, (unknown), Tomohisa Saito, (unknown)	12
6	Phase I Trial of Anti–Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration 2017 ·Ophthalmology Retina ·Usha Chakravarthy, Clare Bailey, David M. Brown, Peter A. Campochiaro, Mark Chittum, Karl G. Csaky, Adnan Tufail, Paul Yates, Patrick G. Cech, (unknown), Paul Delmar, Piotr Szczęsny, Jayashree Sahni, Anne Boulay, (unknown), Sabine Fürst‐Recktenwald, Dietmar Schwab	65
7	Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study 2017 ·BMJ Open Ophthalmology ·Dietmar Schwab, (unknown), Agnès Portron, Sabine Fuerst‐Recktenwald, Dominik Hainzl, Paul Jordan, William C. Stewart, Michael Tepedino, Harvey Dubiner	8
8	What is the biologically relevant KD for VEGF binding to ranibizumab in the eye? A comparison of in-vivo and in-vitro estimates. 2016 ·Investigative Ophthalmology & Visual Science ·Norman A. Mazer, Dietmar Schwab, (unknown), Helen M. Byrne, Eamonn A. Gaffney, Philip K. Maini, Guido Hartmann, (unknown), Christian Gassner, Jörg T. Regula	3
9	The novel bispecific monoclonal anti-VEGF/anti-Ang2 antibody RG7716 shows promise in wet age-related macular degeneration patients with suboptimal response to prior anti-VEGF monotherapy 2016 ·Investigative Ophthalmology & Visual Science ·Usha Chakravarthy, Dietmar Schwab, Patrick G. Cech, (unknown), Anne Boulay, Piotr Szczęsny, Paul Delmar, Jayashree Sahni	1
10	Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2) 2016 ·Hypertension ·Katrijn Bogman, Dietmar Schwab, Marie‐Laure Delporte, Giuseppe Palermo, Kurt E. Amrein, Susanne Mohr, Maria Cristina De Vera Mudry, Morris J. Brown, Philippe Ferber	78
11	A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant Intravenous Microdose Administration of [13C]Tofogliflozin in Humans 2013 ·Clinical Pharmacokinetics ·Dietmar Schwab, Agnès Portron, (unknown), Berthold Lausecker, (unknown)	33
12	Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans 2013 ·Xenobiotica ·M. Zell, Christophe Husser, Olaf Kuhlmann, Dietmar Schwab, (unknown), (unknown), (unknown), (unknown), Axel Pähler	17
13	3,4-Dihydro-2H-benzo[1,4]oxazine derivatives as 5-HT6 receptor antagonists 2007 ·Bioorganic & Medicinal Chemistry Letters ·Shu-Hai Zhao, Jacob Berger, Robin D. Clark, Steven G. Sethofer, Nancy E. Krauss, (unknown), Renée S. Martin, Dinah Misner, Dietmar Schwab, L. А. Alexandrova	34
14	Comparison of in Vitro P-Glycoprotein Screening Assays: Recommendations for Their Use in Drug Discovery 2003 ·Journal of Medicinal Chemistry ·Dietmar Schwab, Holger Fischer, Ali Tabatabaei, Sonia Poli, Jörg Huwyler	157
15	Prolonged blood glucose reduction in mrp-2 deficient rats (GY/TR−) by the glucose-6-phosphate translocase inhibitor S 3025 2002 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Andreas W. Herling, Dietmar Schwab, Hans-Joerg Burger, Jochen Maas, (unknown), Dietmar Schmidt, Sabine Strohschein, Horst Hemmerle, Gerrit Alexander Schubert, Stefan Petry, Werner Kramer	10
16	Pharmacodynamic profile of a novel inhibitor of the hepatic glucose-6-phosphatase system 1998 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·Andreas W. Herling, (unknown), Dietmar Schwab, Horst Hemmerle, Peter Below, Gerrit Alexander Schubert	67
17	Uptake of 3α,7α, 12α-trihydroxy-24-nor-5β-cholan- 23-sulfonate into isolated rat hepatocytes by three transport systems 1997 ·edoc (University of Basel) ·Dietmar Schwab, Bruno Stieger, Bruno Hagenbuch, P.J. Meier, W. Gerok, Gerhart Kurz	1
18	Uptake of 3 alpha, 7 alpha, 12 alpha-trihydroxy-24-nor-5 beta-cholan-23-sulfonate into isolated rat hepatocytes by three transport systems 1997 ·Journal of Lipid Research ·Dietmar Schwab, Bruno Stieger, Bruno Hagenbuch, Peter J. Meier, W. Gerok, Gerhart Kurz	6
19	p53 Mutation and Locoregional Treatment Failure in Head and Neck Squamous Cell Carcinoma 1996 ·JNCI Journal of the National Cancer Institute ·Wayne M. Koch, Jaclyn A. Brennan, Marianna Zahurak, Steven N. Goodman, William H. Westra, Dietmar Schwab, G. Yoo, (unknown), Arlene A. Forastiere, David Sidransky	176
20	Interferon Gamma Enhances Lymphokine-Activated Killer Cell Adhesion but Not Lysis of Head and Neck Squamous Cell Carcinoma 1995 ·Archives of Otolaryngology - Head and Neck Surgery ·Richard L. Scher, (unknown), Dietmar Schwab, William J. Richtsmeier, Wayne M. Koch	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact